Generics US biotech company United Therapeutics’ shares leapt 28.5% to $117.83 on Friday, after the company said that the US District Court for the District of New Jersey has ruled in its favor in the company's case against Sandoz, a generics subsidiary of Swiss pharma giant Novartis, regarding United’s Remodulin (treprostinil) product. 31 August 2014